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Circulating extracellular vesicles have emerged as potential new biomarkers in a wide variety of 
diseases. Despite the increasing interest, their isolation and purification from body fluids remains 
challenging. Here we studied human pre-prandial and 4 hours postprandial platelet-free blood plasma 
samples as well as human platelet concentrates. Using flow cytometry, we found that the majority of 
circulating particles within the size range of extracellular vesicles lacked common vesicular markers. 
We identified most of these particles as lipoproteins (predominantly low-density lipoprotein, LDL) 
which mimicked the characteristics of extracellular vesicles and also co-purified with them. Based on 
biophysical properties of LDL this finding was highly unexpected. Current state-of-the-art extracellular 
vesicle isolation and purification methods did not result in lipoprotein-free vesicle preparations from 
blood plasma or from platelet concentrates. Furthermore, transmission electron microscopy showed 
an association of LDL with isolated vesicles upon in vitro mixing. This is the first study to show co-
purification and in vitro association of LDL with extracellular vesicles and its interference with vesicle 
analysis. Our data point to the importance of careful study design and data interpretation in studies 
using blood-derived extracellular vesicles with special focus on potentially co-purified LDL.
Extracellular vesicles (EVs) are cell-derived submicron structures that have been gaining rapidly increasing atten-
tion in the past decade1–3. Although there is no consensus in the terminology, EVs that originate from mul-
tivesicular bodies and usually have ≤100 nm diameter are referred to as exosomes (EXOs)4, whereas plasma 
membrane-shed vesicles are either called microvesicles (MVs, 100–800 nm) or apoptotic bodies (>1 μm)1–4.
EVs have been found in various body fluids as well as in tissue culture supernatants1–4. Differences in con-
centration and composition of circulating EVs in human blood plasma have been shown to associate with vari-
ous physiological and pathological conditions1,5–9. Circulating EVs originating from diseased tissues may serve 
as biomarkers5–9, and may also enter tissues and exert different functions9–10. The role of pre-analytical condi-
tions has been demonstrated to influence data on circulating EVs11,12. However, the impact of food intake as a 
pre-analytical condition has not been addressed in detail yet.
Blood plasma contains a long known and extensively studied set of particles with a single phospholipid layer 
on their outside, which are known to show robust changes postprandially: lipoproteins13–16. Lipoproteins have 
been studied for decades and low-density lipoprotein (LDL) has been reported as a major risk factor in numerous 
cardiovascular diseases15,17,18.
Current enumeration techniques of circulating particles usually fail to discriminate between vesicular and 
non-vesicular structures such as protein aggregates19. In this study we set to analyze whether in addition to 
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protein aggregates, lipoproteins also have an impact on the detection of EVs. High-density lipoprotein has already 
been identified as a possible contaminant of EV preparations20, and recently association of apolipoprotein E with 
melanocyte-derived exosomes has also been demonstrated21.
Results
Particle concentration within the size range of MVs increases significantly in blood plasma after 
a high-fat meal. To study the effect that food intake has on the detectable particle concentration in blood 
plasma, platelet-free plasma (PFP) was collected from healthy individuals (n = 3) after 12 h fasting as well as at 
multiple time points postprandially, after a standard high-fat meal. Figure 1a,b show flow cytometry (FCM) scat-
ter plots with a significant (up to 5×) increase in the detectable particle number within the MV gate. This increase 
became significant (***P < 0.001) after 90 min (Fig. 1b) and remained elevated even after 6 h. Therefore, in our 
subsequent experiments we chose to use 4 h postprandial PFP samples. As shown in Fig. 1c, TRPS analysis of 
fasting and 4 h postprandial PFPs revealed an increased postprandial particle concentration (*P < 0.05), however, 
without any significant alteration in the particle size (Supplementary Fig. S1). Similarly, tunable resistive pulse 
sensing (TRPS) analysis (a method suitable for measuring particle size and concentration) of PFPs purified on 
a qEVTM size exclusion chromatography (SEC) column (Fig. 1d) maintained the prominent difference between 
fasting and postprandial samples, although there was a general reduction in particle concentration as compared 
to the unpurified samples (Fig. 1c,d).
Figure 1. The impact of food intake on the number of blood plasma particles within the size range of EVs.  
(A,B) Representative scatter plots (A) and summarized data (B) of PFP samples from healthy donors (n = 3), 
analyzed by FCM in fasting state, 15 min, 30 min, 90 min, 180 min and 360 min after a standard high-fat 
meal. The MV gate was established using MegamixTM beads (diameter: 160 nm–500 nm), and the gating was 
optimized with 1 μm silica beads. Note that the particle number within the MV gate significantly increased 
90 min postprandially (mean + SEM, ***P < 0.001, one-way ANOVA), and remained elevated up to 6 h after 
food intake. (C) Representative data of TRPS analysis of fasting and 4 h postprandial human blood plasma 
samples (n = 3, continuous and dotted lines, respectively, *P < 0.05 Wilcoxon matched-pairs signed rank test). 
The samples were measured on NP200, NP400 and NP800 nanopore membranes. (D) TRPS measurement 
(NP200) of fasting (black bars) and 4 h postprandial (gray bars) plasma samples purified with SEC prior to 
TRPS analysis.
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The majority of particles detected in PFP carry lipoprotein markers even in fasting condi-
tions. Next we addressed the question whether these particles that appeared in our FCM analysis postprandi-
ally, could be lipoproteins. Thus, we labelled fasting and 4 h postprandial PFPs (n = 9) with fluorescently labelled 
annexin V (AX) that binds phosphatidyl-serine, as well as anti-CD41a and anti-CD9 antibodies in order to detect 
EVs by FCM. Furthermore, we used an anti-apoB100/48 antibody to detect chylomicrons which have been 
reported to appear in blood ~4 h after food intake16,22 (Fig. 2a, fluorescence-based gating strategy: Supplementary 
Fig. S2). Surprisingly, only a few events within the MV size range carried EV markers, and even this low percent-
age of events was reduced postprandially (Fig. 2b, **P < 0.01). In sharp contrast, most of the particles detected 
within the size range of MVs were recognized by an antibody against human apoB100/B48, even in fasting PFP 
samples. Importantly, the high number of apoB-positive events was significantly increased further in the post-
prandial state (Fig. 2b, ***P < 0.001). In order to identify EVs in our samples, we applied differential detergent 
lysis19,23. Only EV marker positive events which were disrupted in the presence of 0.1% Tx-100 were considered 
EVs, and are presented here. Importantly, we found that some of the apoB-positive events were also sensitive to 
detergent lysis even in fasting conditions (Fig. 2c, ***P < 0.001). However, the remaining apoB carrying events still 
highly outnumbered the disappeared EV marker-bearing ones (up to 20× ). To confirm that lipoproteins appear-
ing postprandially were chylomicrons, we tested whether they float upon ultracentrifugation (UC) as described 
previously22. To this end we analyzed the top fractions of ultracentrifuged fasting and postprandial PFPs by trans-
mission electron microscopy (TEM). As shown in Fig. 2d, floating, electron-dense lipoproteins appeared 4 h 
after food intake. To correlate our findings with routine laboratory measurements, we measured serum triglyc-
eride, total cholesterol, LDL cholesterol, apoA1 and apoB100 content. As shown in Supplementary Table S1, the 
Figure 2. Analysis of particle nature in fasting and postprandial blood plasma samples. (A,B) Representative 
FCM plots (A) and their quantification (B) determined from 10 µL fasting (black bars) and 10 µL 4 h postprandial 
(gray bars) PFP samples of healthy individuals (n = 9, FCM, mean + SEM, ***P < 0.001, Wilcoxon matched-
pairs signed rank test). CD9, AX and CD41a were used to identify MVs, and only events both staining for EV 
markers and sensitive to 0.1% Tx-100 were considered EVs. (C) Number of apoB-positive events within the MV 
gate in fasting (0 h) and postprandial (4 h) states, treated with Tx-100 (mean + SEM, ***P < 0.001, Wilcoxon 
matched-pairs signed rank test). (D) TEM analysis of the top 200 μL fractions of 2.5 mL ultracentrifuged 
(100,000 g, 2 h, 4 °C) fasting and postprandial plasma samples using an “osmification-on-grid” approach. Scale 
bar: 500 nm. Note that highly electron-dense floating particles were detected in the postprandial sample.
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concentration of triglycerides increased significantly (P < 0.05) in postprandial state. This further confirmed that 
these floating particles were chylomicrons which are known to be enriched postprandially in triglycerides22.
MVs isolated from blood plasma and platelet concentrates carry substantial amounts of asso-
ciated lipoproteins. Next we addressed the question whether lipoproteins carrying apoB were also present 
in isolated MV preparations. To test this, we isolated MVs from 500 μL PFP with differential centrifugation and 
gravity-driven size-filtration11,19,24. As shown in Fig. 3a, the percentage of events within the SSC-FSC based MV 
gate increased significantly in the postprandial state (P: 0.0195). However, there was no significant difference in 
the anti-apoB-staining of fasting and postprandial isolated MVs (Fig. 3b). This was most likely due to the fact that 
the already high amount of antibody (optimized for PFP staining) was still not sufficient to label all of the post-
prandially increased number of particles in MV preparations (Supplementary Fig S3). The AX-positive events 
decreased significantly upon food intake (P < 0.0001).
To confirm the vesicular nature of AX-positive events we performed detergent lysis19,23. Surprisingly, not only 
AX-, but also apoB-positive events showed partial sensitivity to 0.1% Tx-100 (Supplementary Fig. S4). We also 
used TRPS to assess the effect of food intake on the number of particles within the MV size range, and found a 
significant increase of particle concentration upon food intake (Fig. 3c and Supplementary Fig. S5).
Given that even in the fasting state the number of apoB-positive particles was at least a magnitude higher 
than the AX-positive ones, we further focused on the analysis and purification of fasting MV samples. We also 
analyzed isolated MVs by TEM, and found striking differences when using two different TEM approaches. While 
ultrathin sections of blood plasma-derived MV pellets (Fig. 3d) showed membrane enclosed vesicular structures, 
analysis of MV suspensions using the “osmification-on-grid” approach revealed highly electron-dense round 
structures within the size range of EVs and in close association with them (Fig. 3e) that were highly reminiscent 
to those shown in Fig. 2d.
We found apoB-positivity in MVs isolated from fasting PFP (Fig. 3a,b), so we decided to investigate whether 
lipoproteins also co-purified with PLT concentrate-derived MVs. For purification we used an OptiprepTM gradi-
ent (Fig. 4a,b). Using FCM and Western blotting, AX and CD63 labelling indicated that MVs were enriched in the 
Figure 3. Detection of apoB-positive particles in isolated MV preparations. (A,B) MVs were isolated by 
differential centrifugation and gravity driven size filtration from 500 μL of fasting PFPs (black bars) and 4 h 
postprandial PFPs (gray bars) and analyzed by FCM. (A) The percentage of events detected within the MV gate 
increased significantly in the postprandial state (n = 9, mean + SEM, *P < 0.05, Wilcoxon matched-pairs signed 
rank test). (b) The isolated MVs were stained with anti-apoB and AX. For the AX labeling only 0.1% Tx-100 
sensitive event s (which we considered EVs) were shown. The difference between the fasting and postprandial 
apoB-positive events was not significant, however, the number AX-positive events decreased significantly upon 
food intake (n = 9, mean + SEM, ****P < 0.0001, paired t-test). (C) Representative TRPS measurement of 
isolated fasting and postprandial MV preparations (continuous line: fasting MVs, dotted line: 4 h postprandial 
MVs). Note that the mean particle size was not affected. (D) TEM image of an ultrathin section prepared from a 
postprandial PFP-derived MV pellet (scale bar: 500 nm). Asterisk indicates MVs. (E) The same sample analyzed 
in suspension by an “osmification-on-grid” approach (scale bar: 500 nm). Note the highly electron-dense, round 
particles reminiscent to the TEM morphology of lipoproteins upon osmification (arrowheads). Membrane 
enclosed MVs (asterisk) showed association with these electron-dense particles.
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6th fraction of the gradient (Fig. 4a) (1.05–1.10 g/mL, Supplementary Fig. S6). Surprisingly, apoB-positive events 
were detectable in almost all fractions (Fig. 4b). Western blot analysis proved that this apoB-positivity was due 
to the presence apoB100 (550 kDa) suggesting that the co-purified particles were mostly LDLs, not chylomicrons 
(bearing apoB48, 260 kDa). Even in the most MV-enriched fraction (FR6), apoB-positive events outnumbered 
the AX-positive ones up to 5× (Fig. 4c). Next, we tested whether SEC resulted in pure PLT-MVs (Fig. 4d). The 
third fraction that contained the most pure population of EVs according to the manufacturer contained still high 
amount of apoB-positive particles measured by FCM.
To further verify the presence of LDL, we carried out MS analysis of MVs isolated from pre- and postprandial 
blood plasma samples. We identified apoB100 protein in both types of samples among the 10 most abundant 
proteins, indicating the presence of LDL in these isolated MV samples (Supplementary Table S2).
LDL co-purifies not only with MVs, but also with EXOs from blood and PLT concentrates. 
Since we detected the co-purification of lipoproteins with MVs, next we tested whether they co-purified with 
EXOs as well. EXOs isolated by differential UC and gravity size filtration from fasting PFP (Fig. 5a) and PLT 
concentrate (Fig. 5b), were bound onto latex beads for FCM analysis. As expected, they stained for EXO mark-
ers such as CD9 and CD63. Importantly, they also showed very high apoB-positivity and a weaker staining for 
apoCII and ApoE. We also analyzed EXOs isolated form postprandial PFPs. We found that even in fasting con-
dition apoB-positive events covered the surface of beads predominantly (>95% was apoB-positive compared to 
the <0.5% CD9/CD63/AX-positivity; data not shown). Postprandially we could not detect a significant further 
increase in the apoB signal. Given the predominant apoB-positivity already present in fasting EXO samples, sim-
ilarly to the analysis of MVs, in our further purification studies we focused on EXOs derived from fasting PFPs 
only.
We purified EXOs from fasting PFP samples on an OptiprepTM density gradient and analyzed the fractions 
by FCM and Western blotting. We found that EXOs were enriched in FR7-8 (1.12–1.18 g/mL, Supplementary 
Fig. S6) as identified by the presence of CD9 and CD63 (Fig. 5c). Lipoproteins were detected mostly in the 
top fractions of the gradient, however, a high amount was also found in the EXO-containing FR7-8 (Fig. 5d). 
Western blotting revealed that the lipoprotein found in the EXO-containing fractions was LDL, since we detected 
apoB100, but not apoB48. Even when we purified EXOs from PLT concentrates on an OptiprepTM gradient, the 
purified particles stained intensively for apoB when analyzed by FCM. This suggests that EV preparations isolated 
from blood or PLT concentrates might contain significant amount of LDL (Fig. 5e).
Figure 4. Purification of PLT concentrate-derived MVs with OptiprepTM density gradient UC and SEC. 
(A,B) Quantification of FCM data and Western-blotting of PLT concentrate-derived MV fractions purified on 
an OptiprepTM density gradient (n = 3, mean + SEM). The event number was detected within the MV-gate. 
MVs were detected by AX (FCM) and CD63 (Western blotting) (A) and lipoproteins by apoB (550 kDa) (B). 
Of note, Western blotting only shows one of the analyzed samples while the FCM shows the average ± SEM 
of 3 measurements. (C) Comparison of the apoB-positive events (black bars) and the AX-positives (gray bars) 
(FCM, n = 2, mean + SEM). (D) SEC purification of MVs isolated from PLT concentrates, fractions analyzed by 
FCM. (apoB: black; AX: gray; CD41a: light gray bars, n = 2, mean + SEM) Note that the apoB-positivity was co-
purified with the EV markers.
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LDL overlaps with the size range of EVs and binds to EVs in vitro. To test the hypothesis that 
the apoB100 positive particles represent LDL, purified human LDL from a commercial source (both from 
Sigma-Aldrich and Merck) was assessed by TRPS as shown in Fig. 5a. Strikingly, the sizes of particles ranged 
from 100 to 500 nm possibly suggesting aggregation of the LDL particles (Fig. 6a). TRPS analysis of LDL at 2 mg/
mL concentration (similar to that of blood plasma25,26) resulted in a two orders of magnitude difference in the 
detected particle number between NP100 and NP200 (Supplementary Fig. S7). The concentration at the average 
diameter of 110 nm was 1.0E13/mL, while the estimated particle number of LDL in human plasma is reported 
to be approximately 1.0E14/mL26, suggesting that we still only see the tip of the iceberg. We also analyzed LDL 
particles conjugated onto latex beads by FCM, and detected apoB and apoCII positivity on the bead surface 
(Fig. 6b). As expected, in the case of LDL no signal was detected for the EV markers CD9 and CD63 (Fig. 6b). We 
next asked whether LDL particles were also detectable by FCM without bead conjugation, and surprisingly, LDL 
at a concentration of 2 mg/mL25,26 was readily detected by FCM. We demonstrated that the signal was caused by 
a swarm effect of LDL particles. Using serial dilution of commercial LDL we have shown that the detected event 
Figure 5. Analysis of apoB-positivity in blood plasma and PLT concentrate-derived EXOs. (A,B) FCM 
detection of the indicated markers in EXOs conjugated onto latex beads. The EXOs were isolated from fasting 
PFP (A) or PLT concentrate (B) by differential UC and gravity size filtration (gray histograms: blocked 
beads incubated with antibody, empty histograms: EXO sample). (C) EXOs from fasting PFP purified on an 
OptiprepTM density-gradient. Distribution of CD9 positive events was determined by FCM (upper panel, 
n = 3, mean + SEM) and CD63 positivity of fractions was determined by Western blotting (lower panel). Of 
note, Western blotting only shows one of the analyzed samples while the FCM shows the average ± SEM of 3 
measurements. (D) The distribution of apoB-positive events determined by FCM (upper panel, n = 3) and by 
Western blotting (lower panel) from the same samples as in (C). (E) PLT-derived EXOs were also purified on a 
density-gradient. The EXO containing FR7-8 was analyzed by FCM for CD9-, CD63- and apoB-positivity (gray 
histograms: blocked beads incubated with antibody, empty histograms: EXO sample).
www.nature.com/scientificreports/
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number increased in the diluted LDL sample (Fig. 6c,d). A similar swarm effect has been reported to influence the 
FCM detection of EVs27. Indeed, we also demonstrated this swarm effect by testing a PFP sample (Supplementary 
Fig. S8). Furthermore, we showed that LDL at the above physiological concentration shared side-scattering prop-
erties with MVs isolated from human blood plasma both in fasting and in postprandial states (Supplementary 
Fig. S9). We also analyzed the detergent sensitivity of commercial LDL and found that LDL was partially sensitive 
to 0.1% Tx-100, possibly due to the disruption of lipoprotein aggregates by the detergent (Fig. 6d).
Next, we investigated further the capacity of LDL to associate with EVs. Using the “osmification-on-grid” 
approach, TEM revealed that commercial LDL was highly similar to the structures that we found in our PFPs 
previously (highly electron-dense round particles) (Fig. 7a). In contrast, MVs isolated from a cell line in serum 
free conditions, showed the typical vesicular morphology (Fig. 7b). Upon in vitro mixing LDL at a concentration 
close to physiological with the cell line-derived MVs, we found that LDL bound extensively onto MVs, covered 
their surfaces, and formed aggregates within the size range of the vesicles (Fig. 7c). Importantly almost all MVs 
were covered with lipoproteins to various extents. We also analyzed the LDL-association of cell-line derived 
EXOs. Upon in vitro mixing the EXOs with LDL, we detected the same phenomenon as with the MVs. The LDL 
particles associated with EXOs, and formed aggregates in the EXO size range as well (Fig. 7d,e). In these experi-
ments we did not perform any additional washing step after mixing LDL with EVs (MVs or EXOs); therefore the 
association of LDL with EVs was not a result of co-pelleting.
Discussion
In recent years EV research has not only achieved high visibility but also attracted an increasing interest from var-
ious fields of biology and medicine. One of the most exciting aspects of EVs in the blood plasma is that they may 
serve as biomarkers in different diseases5–9. Thus, there has been an outstanding interest in blood plasma-derived 
EVs, however, purification of EVs from blood is hampered by the complexity of this bio fluid. In this work we 
introduced modifications in techniques currently used for EV analysis. This enabled us to detect for the first time 
circulating lipoproteins and EVs simultaneously by FCM, Western blotting and TEM.
Our initial finding, the appearance of chylomicrons in postprandial PFP samples, was evidenced by i) the 
elevated serum triglycerides in samples upon food intake, ii) the increased concentration of particles postpran-
dially and iii) the appearance of highly electron-dense particles on the top of ultracentrifuged PFP. Postprandial 
Figure 6. LDL mimics EVs during TRPS and FCM. (A) Commercially available human LDL analyzed by 
TRPS. Note that particles with different sizes were detected within the MV size range (100–800 nm) (measured 
on NP150 and NP300 nanopore membranes, black and gray bars, respectively). (B) FCM analysis of LDL 
particles conjugated to latex beads. Commercial LDL stained for apoB and apoCII, but not for the EV markers 
CD9 and CD63 (black filled histograms: antibody control, empty histograms: LDL). (C) LDL detection by 
FCM without bead conjugation at different dilutions. Note that the measured event number increases with the 
dilution, suggesting a swarm effect. (D) The signal obtained from commercial LDL is also partially sensitive to 
0.1% Tx-100 at a physiological concentration (2 mg/mL) and in the 10 × diluted sample (0.2 mg/mL) as well 
(*P < 0.05, **P < 0.01, Mann-Whitney test).
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triglyceride transportation, floatation behavior upon UC and a characteristic TEM morphology are known fea-
tures of chylomicrons, which have been reported to fall into the size range of 200–600 nm14,22,28,29. Although 
we found chylomicrons to float abundantly only on the top of postprandial PFP samples, surprisingly, a very 
high number of particles in fasting samples also stained with an anti-apoB100/B48 antibody by FCM. In 
blood plasma the vast majority of apoB100 is carried by LDL (~25 nm)14, while less than 10% of it is carried by 
intermediate-density lipoprotein (IDL, ~25–35 nm)16 and very low-density lipoprotein (VLDL, ~30–80 nm)16 
together30. The other isoform of apoB, apoB48 is the marker of chylomicrons31. Distinguishing the two apoB iso-
forms was only possible by Western blotting, because commercial antibodies that recognize apoB100 (550 kDa) 
also react with the truncated form of the protein, apoB48 (260 kDa). Western blot analysis of our samples revealed 
that EVs purified on a density gradient not only carried EV markers but also the apoB100 molecule, suggesting 
that the vast majority of co-purified particles were LDLs. This was true for both MVs and EXOs, either isolated 
from PFP or from PLT concentrates.
As expected, postprandially we could detect chylomicrons by conventional FCM due to their relatively big 
size. Nevertheless, attention has to be paid to the time of blood sampling, as 1 h postprandially chylomicrons 
are still hardly detectable. However, their amount increases rapidly thereafter. In contrast to chylomicrons, the 
concentration of LDL slightly decreases upon food intake32. This stands in line with our finding that routine lab-
oratory determination of apoB100 showed a small decrease in postprandial samples (Supplementary Table S1).
LDL particles are too small to be detected individually by FCM14. However, the concentration of LDL in blood 
plasma is approximately 20,000× higher than that of chylomicrons (2 mg/mL vs. 0.1 mg/L)22,31. This high con-
centration in blood plasma and their high lipid content enabled their detection by conventional FCM due both 
to a swarm effect and their increased scattering properties. Even though FCM is not suitable for determining the 
exact number of LDL particles, we could still gain an insight into their magnitude in blood plasma. Antibodies 
to apoCII and apoE did not give as prominent staining as anti-apoB. This was in line with the fact that apoB100 
constitutes more than 95% of the total protein mass of LDL33 and each LDL particle carries a single copy of 
apoB100 on its surface, while only 10% carries apoE or apoCII14. Taken together, while the postprandial increase 
of apoB-positivity detected in this study was due to the appearance of chylomicrons in blood plasma, the high 
pre-prandial apoB signal was related to LDL.
Figure 7. LDL binds onto isolated MVs and EXOs in vitro. (A,B) TEM analysis of commercial LDL (A) and 
cell line-derived MVs (B) using the “osmification-on-grid” method. LDL particles appear as highly electron-
dense, round structures and show aggregation (A) (scale bars: 500 nm). MVs isolated from the conditioned 
media of a cell line had vesicular morphology (B) (scale bars: 500 nm). (C) TEM images obtained after in vitro 
mixing of commercial LDL with cell-derived MVs for 1 h at room temperature (scale bar: 500 nm). Electron-
dense LDL was observed to bind extensively onto MVs, to cover their surfaces, and to form aggregates in the 
size range of the vesicles. Note that almost all MVs were covered with LDL particles to various extents. (D) TEM 
picture of cell line-derived EXOs (scale bar: 500 nm). (E) Images of cell line-derived EXOs in vitro mixed 
with commercial LDL. Note that the surfaces of the EXOs are covered with LDL particles. The electron dense 
particles in the size range of EXOs represent LDL aggregates (scale bar: 500 nm).
www.nature.com/scientificreports/
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Our analysis revealed that lipoprotein particles were not only detectable by various EV assessment methods, 
but could not be separated from EVs by any of the currently available purification techniques. Importantly, we 
found that incubation of isolated nascent cell-derived EVs with commercial LDL for 1 h at room temperature 
at a concentration characteristic for healthy blood plasma25 resulted in a dramatic attachment of LDL particles 
onto the surface of EVs. The above association was probably mediated by the known interaction of LDL with 
hydrophobic surfaces34 and EVs have been reported to expose the hydrophobic core of their phospholipid bilayer 
because of curvature-related short lived lipid packing defects35. The decreased staining for EV markers in post-
prandial state might be explained by hindrance of vesicle surfaces by the attached lipoproteins. This may at least 
partially explain the presence of the puzzling AX-negative and/or EV-marker negative “orphan” vesicles in bio 
fluids36.
How could we miss lipoprotein particles until now? Why did not we detect them before? Our data suggest that 
lipoproteins are present in such high numbers that we need to use substantially more antibodies than usual in 
order to detect them (Supplementary Fig. S3). Detection of apoB100 with Western blotting is difficult due to its 
very high molecular weight. This is why we chose to use agarose gels to visualize the apoB100 band at 550 kDa by 
Western blotting. Furthermore, EV suspension on-grid analysis by TEM usually involves the use of phosphotung-
stic acid or uranyl acetate, but not OsO44,37,38. Here we used osmification of lipoprotein-containing droplets prior 
to TEM, and this enabled us to visualize lipoprotein particles in our vesicle suspensions isolated from blood 
plasma as highly electron-dense structures.
HDL has been reported to co-purify with EXOs due to its floatation density (1.063–1.21 g/mL) similar to that 
of EXOs20. Our unexpected finding is that LDL which has a floatation density (<1.06 g/mL)14 lower than that of 
either EXOs or HDL particles, is present both in MV and EXO preparations (even after density gradient ultra-
centrifugation). Moreover, it was also present in EV preparations derived from PLT concentrates. Our data are 
supported by a previous MS study that reported the presence of apoA-I, apoB and apoE in blood plasma-derived 
EXO preparations39. Similarly, our MS analysis of fasting and postprandial plasma-derived MVs also showed the 
presence of the above apolipoproteins (Supplementary Table S2). Additionally, looking at this question from an 
entirely different perspective, a proteomic analysis of purified VLDL and LDL has shown the presence of CD14, 
protein S100-A8, HLA class I molecules and LDL-receptor (proteins known to be associated with EVs)40.
The most important practical implication of our data is that LDL resembles circulating EVs (both EXOs and 
MVs) and with the currently used isolation methods cannot be separated from them. Importantly, the size of LDL 
particles is highly variable (Fig. 6a) most likely due to aggregation or fusion of these particles. Both PFP-derived 
apoB-positive particles and purified LDL were partially sensitive to detergent lysis. Thus, detergent sensitive 
events could be either lipoprotein aggregates or MV-lipoprotein complexes. Given the presence of at least one 
order of magnitude higher concentration of LDL particles (Fig. 2b) than EVs, detection of blood plasma-derived 
EVs based on particle enumeration (by nanoparticle tracking analysis or TRPS) might strongly overestimate EV 
numbers. Furthermore, studies conducted with blood-derived EVs should consider the presence of co-purified 
LDL. Thus, our data not only serve the integrity of circulating EV detection but may also provide new insights 
into the pathological processes in which LDL or EVs have been implicated earlier.
Methods
Blood donors. Venous blood was collected from 14 healthy donors (6 males and 8 females, mean age ± SEM: 
27.14 ± 1.77 years, range: 25–30 years) in fasting state and 4 h postprandially. Subjects consumed a high-fat 
standardized breakfast (65% fatty acids, 33.4% protein and 1.6% carbohydrates). During the entire investigation 
period, we followed the guidelines and regulations of the Helsinki Declaration in 1975, and the experiments were 
approved by the Hungarian Scientific and Research Ethics Committee; all tested individuals signed an informed 
consent form.
Blood collection and platelet free plasma (PFP) preparation. We followed a previously described 
protocol11,24 and the guidelines of ISTH on blood sampling and handling for MV analysis41. Briefly, blood was 
collected into acid-citrate-dextrose (ACD-A) tubes (Greiner Bio-One) in order to prevent in vitro release of 
platelet-derived EVs11. Blood was centrifuged 2 × 15 min at 2,500 g. Platelet-free plasma (PFP) was aliquoted, 
snap frozen in liquid nitrogen, and stored at −80 °C until analysis.
Routine laboratory measurements. Routine laboratory determination of serum triglycerides, total cho-
lesterol, LDL cholesterol, apoA1 and apoB100 in fasting and postprandial states was performed in the Central 
Laboratory at Semmelweis University, Budapest, Hungary with a Beckman Coulter AU680 instrument.
EV isolation from PFP. EVs were isolated as described previously11,19,24. Briefly, PFPs were diluted 1:1 
in phosphate-buffered saline (PBS)/annexin binding buffer (ABB: 10 mmol/L HEPES, 140 mmol/L NaCl; 
0.25 mmol/L CaCl2; pH: 7.4–7.5), followed by gravity-driven filtration through a 0.8 μm filter (Whatman). The 
filtrate was centrifuged at 20,500 g, 16 °C for 60 min in a microcentrifuge. The resulting MV pellet was resus-
pended in 50 μL buffer and was analyzed by flow cytometry (FCM). The supernatant was gravity filtered through 
a 0.2 μm filter (Sartorius), and then EXOs were pelleted by ultracentrifugation (UC) at 100,000 g, 4 °C, for 90 min 
(OptimaMAX-XP, MLA-55 rotor, Beckman Coulter Inc).
In some experiments, OptiprepTM-density UC was performed with both MV and EXO pellets as described 
previously42. Briefly, 5, 10, 20 and 40 w/v% OptiprepTM (Sigma-Aldrich) layers were used starting with 40 w/v% 
at the bottom. The sample was layered onto the top, and UC was performed at 100,000 g, 4 °C for 20 h (Beckman 
Coulter OptimaMAX-XP, MLS-50 rotor). Fractions were collected from top to bottom. Each fraction was diluted 
with PBS and centrifuged at 100,000 g (MLA-55 rotor) or in the case of MVs, at 20,500 g. The pelleted fractions 
were either resuspended for FCM or lysed for Western blotting.
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EV isolation from cell line and human platelet concentrates. The 5/4E8 Th1 T hybridoma cell line 
generated by our group43 was cultured as described previously44. For EV production, cells were grown for 24 h in 
serum-free medium. MV and EXO isolation was performed as described previously23,24.
For isolation of platelets (PLT) and PLT-derived EVs, human PLT concentrate was purchased from the 
Hungarian National Transfusion Service, Budapest, Hungary on the day of expiry. For PLT-derived EV isolation 
we used a recently described protocol24,45.
Flow cytometry (FCM). PFP samples were analyzed using a FACSCalibur flow cytometer (BD 
Biosciences). Instrument settings and gates were adopted from previous works11,19,23,24. The MV gate was set 
up by using MegamixTM Beads (Biocytex). Gating was optimized using 1 μm silica beads with a refractory 
index similar to that of EVs (Fig. 1a and Supplementary Fig. S2). All samples were measured at low flow rate 
for 30 sec, the variations in the flow rate of the instrument were assessed by using 1 μm polystyrene calibra-
tion beads with a constant concentration. The flow rate variation was less than 2.5% (21.11 ± 0.52 μL/min) in 
all performed experiments. MV markers were determined in 10 μL PFP using 1 μL of the following reagents 
in 60 μL total volume: annexin-V-PE (AX), anti-CD41a-APC (both from BD Biosciences, anti-CD41a clone: 
HIP8), anti-CD9-FITC, anti-CD63-PE (both from Sigma–Aldrich, clones MEM-61 and MEM-259, respec-
tively). Apolipoprotein B (apoB) staining of PFPs (from 0.2 to 20 μL; Supplementary Fig. S3, lower panel) 
was performed using 4 μL of a goat polyclonal anti-human-apoB100/48-FITC antibody (Mybiosource) 
in a total volume of 60 μL. Self-aggregates of this antibody were removed prior to staining by centrifuging a 
10-fold diluted antibody solution at 20,500 g for 1 h. Only the aggregate-free supernatant was used for sub-
sequent staining (Supplementary Fig. S10). For comparable analysis, data of 10 μL anti-apoB-stained PFP 
is presented. Stainings for apoCII and apoE were performed using 4 μL of goat polyclonal anti-apoCII-FITC 
antibody (Abcam) or 4 μL of anti-apoE-FITC antibody (Novus Biologicals, clone WUE-4). All samples 
were immune labeled at room temperature in the dark for 30 min. After staining, the unbound antibod-
ies were removed by diluting the samples, and pelleting the EVs at 20,500 g (Supplementary Fig. S11). 
To confirm the presence of EVs, we applied detergent lysis and only events that disappeared in the presence of 
0.1% Triton X-100 (Tx-100) were considered vesicles19,23.
MVs were isolated from 500 μL PFP as described previously19,23, resuspended in 20 μL PBS and the same stain-
ings as for PFPs were performed.
Bead-bound EXOs were analyzed by FCM as described previously24. Briefly, they were conjugated onto alde-
hyde/sulfate latex beads (Life Technologies), blocked with 100 mmol/L glycine and 1 w/v% bovine serum albumin 
(BSA) in PBS overnight at 4 °C. After removing the blocking solution (4,000 g; 15 min), the pellet was resuspended 
in PBS for immunostaining.
Flow cytometry data was analyzed with the FlowJo 10.0.8 software.
Tunable Resistive Pulse Sensing (TRPS). PFP samples and EV preparations were analyzed by TRPS 
using a qNano instrument (IZON Sciences Ltd.) as described previously11,23,24,46. Briefly, NP100, NP150, NP200, 
NP300, NP400 and NP800 nanopore membranes were used to measure the samples in serial dilution. We counted 
at least 500 events/sample (in case of very low particle concentration, we measured for 5 min). Calibration was 
performed using calibration beads with a defined concentration, provided by the manufacturer (IZON).
Transmission electron microscopy (TEM) of EVs and LDL. EV-pellets and EV-suspensions were visu-
alized using two different approaches. EV-pellets were processed as described previously6,11,23,24,44,46. Briefly, pellets 
were fixed with 4% paraformaldehyde, postfixed in 1% osmium tetroxide (OsO4) and after rinsing, pellets were 
dehydrated by a series of increasing ethanol concentrations, including block staining with 1% uranyl-acetate in 
50% ethanol for 30 min, and embedded in Taab 812 (Taab). Ultrathin sections were analyzed with a Hitachi 7100 
electron microscope equipped by Veleta, a 2000 × 2000 MegaPixel side-mounted TEM CCD camera (Olympus).
EV suspensions were analyzed by a rapid “osmification on grid” approach22,28. Identical volumes of sus-
pensions of freshly isolated MVs and buffered 1% OsO4 were mixed and placed onto Formvar coated grids 
(10–30 min). Three brief washes in water (3 × 5 min) followed, next contrast staining with 1% uranyl-acetate in 
50% alcohol for 15 min, and finally water again (3 × 5 min). The grids were air-dried and analysed by TEM as 
described above. In the in vitro mixing experiments of LDL and EXOs only OsO4 was used for visualization of 
samples on the grid.
Size exclusion chromatography (SEC). In order to eliminate the lipoproteins present in our samples, 
PFP samples (both from fasting and postprandial individuals) as well as MVs isolated from PLT concentrate 
were subjected to SEC47. We used the qEVTM column of IZON, according to the instructions of the manufacturer. 
Briefly, the column was rinsed with filtered PBS, and then either 0.5 mL of PFP or PLT-MVs in PBS were layered 
onto the top. After collection of a 3 mL void volume, 1 mL EV-containing fraction and further 8 × 1 mL fractions 
were collected. The fractions from plasma were immediately measured by TRPS, whereas the PLT-MVs were 
pelleted at 20,500 g and analyzed by FCM.
Western blot. Five percent agarose (Sigma-Aldrich) was dissolved in a buffer containing 25 mmol/L 
Tris base, 190 mmol/L glycine and 0.1% sodium-duodecyl-sulfate (SDS), and a horizontal gel was prepared. 
OptiprepTM gradient fractions with identical volumes were pelleted, resuspended in lysis buffer, and electro-
phoresed in agarose-SDS gel at constant 100 V for 5 h. Proteins were blotted to PVDF membranes (Bio-Rad). 
Membranes were blocked in 1% BSA in TBS-Tween, and were incubated overnight at 4 °C in the same buffer with 
rabbit polyclonal anti-human-apoB100/48 (Novus Biologicals), or with rabbit monoclonal anti-human-CD63 
(Santa Cruz Biotech). Secondary immunostaining was performed with a goat anti-rabbit-immunoglobulin-HRP 
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conjugate (Abcam). Chemiluminescent signals were detected with the Pierce ECL Western blotting substrate 
(Thermo Fisher Scientific). Blots are shown in Supplementary Figs S12 and S13.
Mass spectrometry (MS). EV pellets were resuspended in 20 μL water and proteins were extracted using 
repeated freeze-thaw cycles44. Proteins were digested as described previously48. The peptide digest was analyzed 
using a Bruker Maxis II Q-TOF instrument with CaptiveSpray nanoBooster ionization source. Peptides were 
separated online using a 25 cm Acclaim Pepmap RSLC nano HPLC column on the Dionex Ultimate 3000 Nano 
LC System. Data were evaluated with ProteinScape 3.0 software, using Mascot search engine.
Statistics and data analysis. Statistical analysis was performed with GraphPad Prism v.6 software. For 
comparison of fasting and postprandial samples, we used paired t-test or Wilcoxon matched-pairs signed rank 
test. Samples were tested for normality with the D’Agostino-Pearson normality test. For comparison of several 
groups 1-way ANOVA was used followed by Dunnetts post-hoc test. (*P < 0.05, **P < 0.01 and ***P < 0.001). 
Error bars indicate standard error of the mean (SEM).
Images were edited with the Adobe Photoshop CS5 software.
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